Biotechnology: Biological Products (No Diagnostic Substances)

Management ChangeJun 8, 2026, 04:07 PM

Kymera Therapeutics COO Jeremy Chadwick Resigns

AI Summary

Kymera Therapeutics, Inc. announced that Jeremy Chadwick communicated his intention to retire and submitted his resignation as Chief Operating Officer on June 5, 2026. Mr. Chadwick will remain with the company as an advisor until November 2026. He cited personal reasons for his departure, confirming no disagreement with the company's practices or policies.

Key Highlights

Kymera Therapeutics COO Jeremy Chadwick resigned on June 5, 2026.
Mr. Chadwick will transition to an advisory role until November 2026.
His resignation is for personal reasons, not due to any disagreement with company policies.

View SEC Filing

KYMR

Biotechnology: Biological Products (No Diagnostic Substances)

Kymera Therapeutics, Inc.

Price Impact